Lynparza demonstrates survival benefit in early breast cancer, phase III trial data show

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AstraZeneca and Merckannounced long-term results from the OlympiA phase III trial which showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival and distant disease-free survival for people with germline BRCA-mutated HER2-negative high-risk early breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Primary results from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz), a humanized monoclonal antibody targeting programmed death receptor-1, in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer who have not been previously treated with systemic chemotherapy, were published in The Lancet. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login